Cardinal Health (NYSE:CAH) Updates FY25 Earnings Guidance

Cardinal Health (NYSE:CAH) issued an update on its FY25 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of at least $7.50 for the period, compared to the consensus estimate of $7.89. Cardinal Health also updated its FY24 guidance to $7.30-7.40 EPS.

Cardinal Health Price Performance

Shares of CAH stock traded up $1.49 during trading hours on Thursday, reaching $103.66. 540,911 shares of the company traded hands, compared to its average volume of 2,234,539. The company has a market cap of $25.21 billion, a P/E ratio of 40.22, a P/E/G ratio of 1.04 and a beta of 0.71. Cardinal Health has a 12-month low of $77.56 and a 12-month high of $116.04. The firm has a 50-day moving average price of $109.37 and a 200 day moving average price of $104.98.

Cardinal Health (NYSE:CAH) last announced its quarterly earnings results on Thursday, February 1st. The company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.56 by $0.26. Cardinal Health had a net margin of 0.30% and a negative return on equity of 57.44%. The company had revenue of $57.45 billion for the quarter, compared to the consensus estimate of $57.02 billion. During the same period in the previous year, the firm posted $1.32 EPS. Cardinal Health’s revenue for the quarter was up 11.6% compared to the same quarter last year. Sell-side analysts predict that Cardinal Health will post 7.28 EPS for the current year.

Cardinal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Monday, April 1st were paid a dividend of $0.5006 per share. This represents a $2.00 annualized dividend and a yield of 1.93%. The ex-dividend date of this dividend was Thursday, March 28th. Cardinal Health’s payout ratio is 78.74%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. UBS Group raised their target price on shares of Cardinal Health from $122.00 to $125.00 and gave the stock a buy rating in a research report on Monday, February 5th. Barclays assumed coverage on Cardinal Health in a research note on Wednesday, January 3rd. They issued an overweight rating and a $117.00 target price on the stock. SVB Leerink began coverage on Cardinal Health in a research report on Monday, February 26th. They issued an outperform rating and a $125.00 price objective for the company. Wells Fargo & Company lowered their target price on shares of Cardinal Health from $96.00 to $94.00 and set an underweight rating for the company in a research note on Monday. Finally, StockNews.com raised Cardinal Health from a buy rating to a strong-buy rating in a report on Thursday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $102.93.

About Cardinal Health

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.